Kynam Capital Management’s Caribou Biosciences CRBU Stock Holding History

Kynam Capital Management’s Portfolio CRBU Stock Details CRBU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.76M	Hold	2,503,302	–	–	0.29%	35
2025 Q4	$3.98M	Sell	2,503,302 -564,472	-18%	-$1.18M	0.25%	32
2025 Q3	$7.15M	Hold	3,067,774	–	–	0.53%	29
2025 Q2	$3.87M	Sell	3,067,774 -201,373	-6%	-$198K	0.42%	24
2025 Q1	$2.99M	Buy	3,269,147 +863,000	+36%	+$1.12M	0.25%	29
2024 Q4	$3.83M	Buy	2,406,147 +50,000	+2%	+$101K	0.23%	28
2024 Q3	$4.62M	Buy	2,356,147 +709,445	+43%	+$1.45M	0.35%	23
2024 Q2	$2.7M	Buy	1,646,702 +578,175	+54%	+$1.85M	0.21%	25
2024 Q1	$5.49M	Hold	1,068,527	–	–	0.57%	21
2023 Q4	$6.12M	Hold	1,068,527	–	–	0.68%	22
2023 Q3	$5.11M	Buy	+1,068,527	New	+$6.63M	0.84%	21

Other funds holding CRBU

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kynam Capital Management's CRBU Position: Q1 2026 in Review

Kynam Capital Management held its Caribou Biosciences (CRBU) position steady in Q1 2026 at 2,503,302 shares worth $4.76M. The position accounts for 0.29% of the portfolio, ranked #35.

Kynam Capital Management first reported a position in CRBU in Q3 2023 and has held it in 11 quarters since. The position peaked at $7.15M in Q3 2025. 137 funds tracked by Wall St. Rank hold CRBU as of Q1 2026.

Kynam Capital Management held 2,503,302 shares of Caribou Biosciences worth $4.76M as of Q1 2026.
Kynam Capital Management left its Caribou Biosciences share count unchanged in Q1 2026.
Caribou Biosciences made up 0.29% of Kynam Capital Management's portfolio in Q1 2026, its #35 holding.
Kynam Capital Management first reported a position in Caribou Biosciences in Q3 2023 and has held it in 11 quarters since.
Kynam Capital Management's Caribou Biosciences position peaked at $7.15M in Q3 2025.
137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q1 2026.

Based on Kynam Capital Management's 13F filing for Q1 2026, filed 15 May 2026.